Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-03-01
2011-03-01
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S144100, C424S805000, C530S324000, C530S326000, C530S387100, C530S388220, C530S868000
Reexamination Certificate
active
07897151
ABSTRACT:
The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
REFERENCES:
patent: 4208479 (1980-06-01), Zuk et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5601821 (1997-02-01), Stanworth et al.
patent: 5629415 (1997-05-01), Hollis et al.
patent: 5653980 (1997-08-01), Hellman et al.
patent: 5965709 (1999-10-01), Presta et al.
patent: 6734287 (2004-05-01), Lawton et al.
patent: 6887472 (2005-05-01), Morsey et al.
patent: 6913749 (2005-07-01), Hellman
patent: 0263655 (1988-04-01), None
patent: 0 957 111 (1999-11-01), None
patent: 09169795 (1997-06-01), None
patent: 88/00204 (1988-01-01), None
patent: 9206180 (1992-04-01), None
patent: 9220316 (1992-11-01), None
patent: 9222635 (1992-12-01), None
patent: 9305810 (1993-04-01), None
patent: 9314188 (1993-07-01), None
patent: 9320221 (1993-10-01), None
patent: 9408598 (1994-04-01), None
patent: 9412649 (1994-06-01), None
patent: 9731948 (1997-09-01), None
patent: 9824808 (1998-06-01), None
patent: WO 98/24808 (1998-06-01), None
patent: WO 99/67293 (1999-06-01), None
patent: 9967293 (1999-12-01), None
patent: 00/23477 (2000-04-01), None
Machine translation of JP 09169795, translated May 27, 2009.
Partial European Search Report, EP 09154655.6 dated Apr. 24, 2009.
Kozarsky and Wilson, “Gene therapy: adenovirus vectors”, Current Opinion in Genetics and Development, 3:499-503, 1993.
Extended European Search Report, EP 08156885.9 dated Dec. 10, 2008 (9 pages).
Nio, et al.,Inhibition of passive cutaneous anaphylaxis by synthetic human immunoglobulin E peptide fragments, FEBS 11869, vol. 314, No. 3, 229-231 (1992).
Harlow et al in Antibodies a Laboratory Manual, 1998, Cold Spring harbor laboratory publication, Cold Spring Harobr, NY, p. 129.
Shakib, et al.; Identification of Peptide Motifs Recognized by a Human IgG Autoanti-IgE antibody Using a Phase Display Library; Clinical and Experimental Allergy; vol. 30 No. 7, pp. 1041-1046 (2000) XP001055645.
Burt, et al.; Eur. J. Immunol.; Inhibition of Binding of Rat IgE to rat mast Cells by Synthetic IgE Peptides; vol. 17:43-440 (1987).
Helm, et al.; Nature; The Mast Cell Binding Site on Human Immunoglobulin E; vol. 331: 180-183 (1988).
Helm, et al.; Proc. Natl. Acad. Sci.; Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human c-chain fragment of 76 amino acids; vol. 86, p. 9465-9469 (1989).
Vercelli, et al.; Nature; The B-Cell binding site on human immunoglobulin E; vol. 338:649-651 (1989).
Nio, et al.; FEBS Letter; Inhibition of passive sensitization of human peripheral basophils by synthetic human immunoglobulin E peptide fragments; 319:225-228 (1993).
Nio, et al.; FEBS Letter; Inhibition of passive cutaneous anaphylaxis by synthetic human immunoglobulin E peptide fragments; vol. 314, No. 3, p. 229-231 (1992).
Basu, et al.; The J. of Biological Chemistry; Purification and Characterization of Human Recombinant IgE-Fc Fragments that Bind to the Human High Affinity IgE Receptor; vol. 268, No. 18, p. 13118-13127 (1993).
Vangelista, et al.; The J. of Clinical Investigation; The Immunoglobulin-like modules Cε3 and α2 are the minimal units necessary for human IgE-FcεRI interaction; vol. 103: p. 1571-1578 (1999).
Robertson, et al.; Molecular Immunology; IgE Structure-Function relationships Defined by Sequence Directed Antibodies Induced by Synthetic Peptides; vol. 25, No. 2, p. 103-113 (1988).
Schwarzbaum, et al.; European J. of Immunology; Mapping of Murine IgE Epitopes Involved in IgE-FcεReceptor Interactions; 19:1015-1023 (1989).
Weetall, et al.; The J. of Immunology; Mapping the Site of Interaction between Murine IgE and its High Affinity Receptor with Chimeric Ig1; 145:3849-3854 (1990).
Presta, et al.; The J. of Biological Chemistry; The Binding Site on Human Immunoglobulin E for Its High Affinity Receptor; 269:26368-26373 (1994).
Nissim, et al.; The J. of Immunology; Fine Specificity of the IgE Interacton with the Low and High Affinity Fc Receptor1; 150:1365-1374 (1993).
Del Prado, et al.; Molecular Immunology; Monoclonal Antibodies Against Human IgE, Identification of an Epitope Sharing Properties with the High-Affinity Receptor Binding Site; 28:839-844 (1991).
Keegan, et al.; Molecular Immunology; Characterization of New Rat Anti-Mouie IgE Monoclonals and their use along with Chimeric IgE to Further Define the Site that Interacts with FcεRII and RcεRI; 28:1149-1154 (1991).
Hook, et al.; Molecular Immunology; Monoclonal Antibodies Defining Epitopes on Human IgE; 28:631-639 (1991).
Takemoto, et al.; Microbiol. Immunology; Anti-Human IgE Monoclonal Antibodies Recognizing Epitopes Related to the Binding Sites of High and Low Affinity IgE Receptors; 38(1), p. 63-71 (1994).
Baniyashi, et al.; Molecular Immunology; Anti-IgE Monoclonal Antibodies Directed at the FcεReceptor Binding Site; 25:705-711 (1988).
Chang, T.W.; Nature; The Pharmacological Basis of Anti-IgE Therapy; 157-162 (2000).
Presta, et al.; The J. of Immunology; Humanization of an Antibody Directed Against IgE; 151:2623-2632 (1993).
Stadler, et al.; Int. Arch Allergy Immunol.; Biological Activities of Anti-IgE Antibodies; 102:121-126, 1993.
Rudolf, et al.; J. of Immunology; Epitope-Specific Antibody Response to IgE by Mimotope Immunization1; 160:3515-3321, 1998.
Xiu-min Li, et al.; J. Allergy Clin. Immunology; A Murine Model of IgE-mediated cow's milk hypersensitivity; 103:206-214 (1999).
Xui-Min Li, et al.; J. Allergy Clin. Immunology; Murine Model of Atopic Dermatitis Associated with Food Hypersensitivity; 107:693-702 (2001).
Ermel, et al.; Laboratory Animal Science; The Atopic Dog: A Model for Food Allergy; vol. 47, No. 1, p. 40-48 (1997).
McDermott, et al.; Molecular Immunology; Identification, cloning, and characterization of a major cat flea salivary allergen (Cte f 1) 37:361-375 (2000).
Underwood, et al.; Immunology; IgE Production, Antigen-induced airway inflammation and Airway Hyperreactivity in the Brown Norway rat: the Effects of Ricin; 85:256-261 (1995).
Underwood, et al.; Int. Arch Allergy Immunology; Ricin Increases IgE Levels and Airway Inflammation but Not Hyperresponsiveness in the Rat; 107:119-121 (1995).
Diaz-Sanchez, et al.; Immunology; Generation of a long-lived IgE Response in High and Low Responder Strains of rat by co-administration of Ricin and Antigen; Immunology; 72:297-303 (1991).
Noble, et al.; Immunology; Elimination of IgE Regulatory Rat CD8+T Cells in Vivo Increases the Co-ordinate Expression of Th2 cytokines IL-4, IL-5 and IL-10; 80:326-329 (1993).
Diaz-Sanchez, et al.; Immunology; Ricin Enhances IgE responses by Inhibiting a Subpopulation of Early-Activated IgE Regulatory CD8+T Cells; 78:226-236 (1993).
Karlin, et al.; Proc. Natl. Acad. Sci.; Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes; vol. 87, p. 2264-2268 (1990).
Karlin, et al.; Proc. Natl. Acad. Sci.; Applications and Statistics for Multiple High-scoring Segments in Molecular Sequences; vol. 90, p. 5873-5877 (1993).
Pearson, et al.; Proc. Natl. Acad. Sci.; Improved Tools for Biological Sequence Comparison; vol. 85, p. 24444-2448(1988).
Benoist, et al.; Nature; In Vivo Sequence Requirements of the SV40 Early Promoter Region; 290:304-310 (1981).
Yamamoto, et al.; Cell; Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sarcoma Virus; vol. 22, p. 787-797 (1980).
Wagner, et al.; Proc. Natl. Acad. Sci.; Nucleotide Sequence of the Thymidine Kinase Gene of Herpes Simplex Viru
Morsey Mohamad A.
Sheppard Michael G.
Wheeler David W.
Gumbleton Timothy J.
Pharmacia & Upjohn Company LLC
Szperka Michael
LandOfFree
Anti-IgE vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IgE vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IgE vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741931